FDA Approved PURE Control Antimicrobial Poultry Processing Aid Introduced
As Non-Toxic Intervention to Dramatically Reduce Salmonella
SAN DIEGO (Feb 01, 2016) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the FDA approved, patented silver dihydrogen citrate (SDC) antimicrobial, announced that the Company introduced PURE Control® at IPPE (International Production & Processing Expo) last week. IPPE is the world's largest annual poultry, meat and feed industry event attended by more than 30,000 industry leaders and their suppliers seeking to learn about the latest technological developments in the industry.
PURE Control is a leading-edge antimicrobial processing aid for direct application to poultry during processing to reduce pathogen populations. It maximizes microbial control and is highly effective against Salmonella, Listeria, E. coli and many other pathogens. SDC test results show the potential to reduce Salmonella on raw poultry to below detection levels.
Since receiving recent validation from its two FDA approvals (for fresh produce processing and for raw poultry processing), PURE Control is generating significant interest from both processors and distributors who are evaluating bringing in PURE Control as a processing aid. This is opening up a combined processing aid market opportunity in excess of $650 million, of which PURE expects to gain a significant share based on SDC’s compelling competitive advantages.
The final step in the regulatory approval process for PURE Control for poultry processing is to obtain USDA approval. The approval process will involve plant trials under the authorization of the USDA which are expected to be completed by early calendar Q2. PURE will then begin immediate commercialization.
Expo Meetings Highlights
Throughout the Expo, the PURE team had a series of productive meetings with many of the leading poultry processors and their chemical distributors:
Processors at the show emphasized to PURE that the persistence of Salmonella and Campylobacter remains their biggest challenge, and expressed keen interest in bringing PURE Control into their plants following the successful completion of the USDA plant trials.
Significant interest was expressed in the economic value of the indication that PURE Control used in poultry processing has a neutral to positive impact on yield, with no adverse organoleptic or nutritional impacts.
Processors were attracted by the fact that PURE Control is a non-toxic intervention vs. other interventions commonly used in poultry processing today.
PURE’s sales and marketing team have already begun follow up to set on-site meetings and/or provide more detailed test data and information.
Hank R. Lambert, CEO, said that, “Based upon the quantity and quality of the meetings at the Expo, I feel confident that upon successful completion of the USDA trials, the adoption of PURE Control for raw poultry processing will rapidly build momentum. We currently have a number of the largest poultry processors using PURE® Hard Surface for environmental and surface disinfection and I have every reason to expect that they will be among the first to take in PURE Control to help eliminate Salmonella.”
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including acceptance of the Company’s PURE Control as a fresh produce processing aid and the Company’s ability to convert successful evaluations into customer orders; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw poultry and raw meat processing; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2015 and its Form 10-Q for the first quarter ended October 31, 2015. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Hank Lambert, CEO
PURE Bioscience, Inc.
Terri MacInnis, Director of IR
Bibicoff + MacInnis, Inc.
Redwood Investment Group